| Name | Title | Contact Details |
|---|
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company`s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases.
Based in Redmond, WA, EndoGastric Solutions, Inc., is a medical device company focused on developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of gastroesophageal reflux disease (GERD). EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) procedure—a minimally invasive solution that addresses a significant unmet clinical need.
MedPoint Communications, Inc is a Evanston, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Comprehensive Care Services is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Monarch Medical Technologies is a digital health company committed to helping hospitals and health systems deliver optimal glycemic management for critical care and non-critical care patients alike. Insulin dosing has always been a daunting and time-intensive task, but now that burnout and staffing constraints have reached record highs, never have the associated risks and challenges been more acute. Add the impacts of new CMS measures for hyperglycemia and hypoglycemia, and you have the perfect storm. Our FDA-cleared EndoTool® Glucose Management System is designed specifically to displace traditional manual methods of insulin dosing with an intuitive and easy-to-use software application that integrates seamlessly with your EMR. This pioneering clinical decision support platform offers both intravenous and subcutaneous modalities, and has been shown to safely and reliably achieve and maintain target glucose goals. Specialized features help clinicians address the complexities surrounding diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic nonketotic syndrome (HHS), gestational diabetes, kidney function, residual insulin, and presence of steroids.